Black Titan Corp (NASDAQ:BTTC) Stock Short Interest Declines 66.4%

Black Titan Corp (NASDAQ:BTTC) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 104,106 shares, a decrease of 66.4% from the October 15th total of 309,564 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 260,364 shares, the days-to-cover ratio is presently 0.4 days.

Black Titan Price Performance

NASDAQ BTTC traded up $0.02 during midday trading on Friday, hitting $0.32. The company had a trading volume of 46,920 shares, compared to its average volume of 3,915,652. The company has a market capitalization of $3.46 million, a PE ratio of -0.11 and a beta of 1.21. The company has a current ratio of 4.40, a quick ratio of 4.62 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $0.42 and a 200-day moving average price of $0.96. Black Titan has a twelve month low of $0.28 and a twelve month high of $10.05.

Black Titan (NASDAQ:BTTC) last released its earnings results on Friday, November 6th. The company reported ($0.10) earnings per share (EPS) for the quarter.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.